| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
4.64
|
|
2
|
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
|
J Clin Oncol
|
2002
|
3.05
|
|
3
|
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
|
J Clin Oncol
|
2008
|
2.09
|
|
4
|
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.
|
Cancer
|
2011
|
1.66
|
|
5
|
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.
|
Am J Clin Pathol
|
2002
|
1.57
|
|
6
|
ACCO: ASCO core curriculum outline.
|
J Clin Oncol
|
2005
|
1.20
|
|
7
|
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
|
J Clin Oncol
|
2002
|
1.15
|
|
8
|
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
|
Clin Cancer Res
|
2012
|
1.04
|
|
9
|
A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).
|
Am J Clin Oncol
|
2010
|
0.96
|
|
10
|
Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
|
Lancet
|
2008
|
0.90
|
|
11
|
SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.87
|
|
12
|
Targeted therapies: Improved outcomes for patients with metastatic melanoma.
|
Nat Rev Clin Oncol
|
2011
|
0.82
|
|
13
|
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
|
Cancer
|
2010
|
0.81
|
|
14
|
Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.
|
Anticancer Drugs
|
2007
|
0.79
|
|
15
|
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
|
Cancer
|
2007
|
0.79
|
|
16
|
Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
|
Invest New Drugs
|
2006
|
0.77
|
|
17
|
A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
|
Invest New Drugs
|
2002
|
0.75
|
|
18
|
New options for the adjuvant treatment of cutaneous melanoma?
|
Curr Oncol Rep
|
2014
|
0.75
|